Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Abstract Human epidermal growth factor receptor 2 (HER2) overexpression emerges as an attractive therapeutic target in gynecological malignancies. Recently, Trastuzumab-Deruxtecan (T-DXd) has shown substantial efficacy in HER2 overexpressing carcinomas, most prominently in ovarian, endometrial and c...

Full description

Bibliographic Details
Published in:BMC Cancer
Main Authors: Angeliki Andrikopoulou, Flora Zagouri, Kallirroi Goula, Dimitrios Haidopoulos, Nikolaos Thomakos, Anna Svarna, Meletios-Athanasios Dimopoulos, Michalis Liontos
Format: Article
Language:English
Published: BMC 2024-12-01
Subjects:
Gynecologic cancer
HER2
T-DXd
DS-8201
Endometrial cancer
Ovarian cancer
Online Access:https://doi.org/10.1186/s12885-024-13226-1

Internet

https://doi.org/10.1186/s12885-024-13226-1

Similar Items